Compare Nasdaq Inc (NDAQ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Nasdaq (NDAQ) trades at $90.24, down 1.53% today, with a bullish technical signal from moving averages and a consensus analyst price target of $107.00. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.96 exceeding expectations, and maintains robust profitability with a net income margin of 23.03%. Recent news highlights strategic growth, including the acquisition of Nasdaq Fund Secondaries by NPM, expanding its platform beyond direct company shares.

The outlook for NDAQ is positive, supported by organic revenue growth and strategic acquisitions, though risks include market volatility and execution challenges. With 61.11% of analysts rating it a buy and a price target implying ~19% upside, the stock presents a growth opportunity for investors focused on financial infrastructure expansion, balanced by monitoring debt levels and competitive pressures.

Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.

The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.